{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:59:48Z","timestamp":1788951588820,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Seattle Genetics, Inc."},{"name":"Millennium Pharmaceuticals, Inc."}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bbmt.2018.05.026","type":"journal-article","created":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T13:28:48Z","timestamp":1527686928000},"page":"2354-2359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting"],"prefix":"10.1016","volume":"24","author":[{"given":"Auayporn","family":"Nademanee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-9340","authenticated-orcid":false,"given":"Patrick","family":"Stiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Holowiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer","family":"Abidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Hunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pecsok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Uttarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Purevjal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sweetenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.05.026_bib0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0015","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0025","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 4","key":"10.1016\/j.bbmt.2018.05.026_bib0035","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0040","series-title":"Adcetris (brentuximab vedotin) [package insert]","year":"2017"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0045","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0050","first-page":"1","article-title":"Brentuximab vedotin after autologous stem cell transplant (ASCT) yields the strongest benefit in Hodgkin lymphoma (HL) patients with \u2265 2 risk factors: results of a multivariate analysis (MVA)","volume":"1","author":"Moskowitz","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1188\/13.CJON.138-144","article-title":"Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management","volume":"17","author":"Tofthagen","year":"2013","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","article-title":"Toxic neuropathy in patients with pre-existing neuropathy","volume":"60","author":"Chaudhry","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1188\/06.ONF.347-352","article-title":"Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia","volume":"33","author":"Donohue","year":"2006","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0070","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Infectious Diseases Society of America: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clml.2015.02.024","article-title":"Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades","volume":"15","author":"Bhatt","year":"2015","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0085","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0090","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","article-title":"New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors","volume":"21","author":"Baker","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/oxfordjournals.annonc.a058662","article-title":"High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients","volume":"4","author":"Bierman","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2018.05.026_bib0100","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/bjh.14316","article-title":"Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma","volume":"175","author":"Ramsey","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118302982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118302982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:39Z","timestamp":1761059019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118302982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1083879118302982"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.026","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}